Dong-A ST is attempting to make another leap with ‘Actonel,’ a bisphosphonate drug that is now sold exclusively by the company.

According to industry sources, Dong-A ST has been working to land Sanofi’s bisphosphonate osteoporosis treatment Actonel (risedronate) at major medical institutions in Korea after it started to exclusively supply the drug in October last year.

As of now, the drug has passed the drug committees (DCs) of 64 medical institutions including the ‘Big 5 tertiary hospitals’ of Korea - the Seoul National University Hospital, Seoul Asan Medical Center, Sinchon Severance Hospital, etc.

Actonel, which is one of the representative bisphosphonate bone re